Weiguang Biology: 2025 Board of Directors Work Report
Shenzhen Weiguang Biological Products Co., Ltd.
2025 Annual Board of Directors Work Report
In 2025, the board of directors of Shenzhen Weiguang Biological Products Co., Ltd. (hereinafter referred to as the company) strictly complied with relevant regulations such as the Company Law, Securities Law, Articles of Association, and Rules of Procedure of the Board of Directors, conscientiously performed the various powers granted by the company and shareholders, fully implemented the resolutions of the shareholders' meeting, carried out various tasks diligently and responsibly, effectively safeguarded the interests of the company and all shareholders, continued to improve the corporate governance system, and continuously improved the level of standardized operations. The main work of the company’s board of directors in 2025 is now reported as follows:
1. The company’s operating conditions in 2025
During the reporting period, the company in-depth implemented the "four major improvement" actions of scale improvement, efficiency improvement, benefit improvement, and market value improvement. All work was improved in quality and efficiency, and multiple key areas such as pulp extraction, production operations, R&D innovation, market expansion, and brand building achieved all-round improvements, laying a solid foundation for a high-quality start to the "15th Five-Year Plan". In 2025, the company achieved operating income of 1.267 billion yuan, a year-on-year increase of 5.28%; net profit was 246 million yuan, a year-on-year decrease of 2.84%. For details of the company's operating conditions during the reporting period, please refer to the relevant content of "Section 3 Management Discussion and Analysis" of the 2025 Annual Report.
2. Performance of duties of the Board of Directors in 2025
(1) Operations of the board of directors
During the reporting period, the company's board of directors held a total of 9 meetings. The convening, holding, voting procedures and content of the meeting's proposals complied with the provisions of the Company Law, Articles of Association, and Rules of Procedure of the Board of Directors. All directors attended all board meetings in person and did not miss two consecutive board meetings. The details of the board meetings during the reporting period are as follows:
Serial number Meeting name Meeting time Proposal to be considered
"Proposal on the 2024 Annual Report and its Summary"
"Proposal on the 2024 General Manager Work Report"
"Proposal on the 2024 Board of Directors Work Report"
"Proposal on the Profit Distribution Plan for 2024"
"Proposal on the 2024 Internal Control Self-Evaluation Report" Third Board of Directors 6. "Proposal on Increasing the Bank's Comprehensive Credit Line"
The third meeting of the Board of Directors April 7, 2025. "Proposal on the implementation of daily related transactions in 2024 and the expected daily related transactions in 2025"
Proposal 8. "Proposal on the <Shenzhen Weiguang Biological Products Co., Ltd. Phase III Employee Stock Ownership Plan (Second Revision of the Draft)> and its Summary"
"Proposal on the Management Measures for the Third Phase Employee Stock Ownership Plan of Shenzhen Weiguang Biological Products Co., Ltd. (Second Revised Draft)"
"2024 Environmental, Social and Corporate Governance (ESG) Report"
motion
- "Proposal on Convening the 2024 Annual General Meeting of Shareholders"
3rd Board of Directors
Business meeting No. 3 04, 2025
2 "Proposal on the <2025 First Quarter Report>"
Thirteenth meeting on the 21st of the month
discuss
- "Proposal on Amending the Articles of Association and Handling Industrial and Commercial Change Registration" 2. "Proposal on Amending the Company's Related Systems"
3rd Board of Directors
- "About the General Election and Nomination of the Company's Board of Directors Non-Individual Meeting of the Fourth Board of Directors No. 3 July 2025
3 Proposal on Candidates for Directors”
Fourteenth meeting, month 01
- "Independent Meeting on the Election and Nomination of the Fourth Board of Directors of the Company"
Proposal for Director Candidates"
"Proposal on Convening the First Extraordinary General Meeting of Shareholders in 2025"
"Proposal on the Election of Chairman of the Fourth Board of Directors"
"Proposal on the election of members of the special committees of the fourth session of the Board of Directors" 3. "Proposal on the appointment of senior managers and securities affairs representatives" 4. "Proposal on the remuneration plan for directors of the fourth session of the Board of Directors" 5. "Proposal on the remuneration plan for the company's senior managers"
"Proposal on meeting the conditions for issuance of A shares to specific objects" 7 ". Proposal on the plan to issue A shares to specific objects in 2025" 8 ". Proposal on the plan to issue A shares to specific objects in 2025" 9 ". Proposal on the demonstration and analysis report on the plan to issue A shares to specific objects in 2025"
4th Board of Directors
2025 07 10. "About raising funds from the issuance of A shares to specific objects in 2025 4 Board of Directors meeting first
Proposal to use feasibility analysis report on March 17th
meetings
"Proposal on the need to prepare a report on the use of previously raised funds" 12. "Proposal on the issuance of A shares to specific objects in 2025 to dilute current shareholder returns, filling measures and commitments of relevant entities"
"Proposal on requesting the general meeting of shareholders to authorize the board of directors or persons authorized by the board of directors to fully handle matters related to the issuance of A shares to specific objects" 14. "Proposal on shareholder dividend return planning for the next three years (2025-2027)"
"Proposal on Investment in Weiguang Bio-Intelligent Industrial Base Project" 16. "Proposal on Adjusting the Estimated Amount of Daily Related Transactions in 2025" 17. "Proposal on Convening the Second Extraordinary General Meeting of Shareholders in 2025"
4th Board of Directors
2025 08
5 Board Meeting No. 2 "Proposal on the Proposal to Participate in the Bidding for the Use Rights of State-owned Construction Land"
15th
meetings
4th Board of Directors
2025 8
6 Board of Directors No. 3 "Proposal on the <2025 Semi-annual Report> and its Summary"
March 28
meetings
4th Board of Directors
10, 2025
7 Board Meeting No. 4 "Proposal on the <Third Quarter Report of 2025>"
March 29
meetings
The Fourth Board of Directors 1. "Proposal on Appointment of Secretary to the Board of Directors"
11, 2025
8 Board Meeting No. 5 2. "Proposal on Renewal of the Audit Institution for 2025"
month 11
Meeting 3. "Proposal on Convening the Third Extraordinary Shareholders' Meeting in 2025"
- "Proposal on Applying for a Comprehensive Credit Line from the Bank"
4th Board of Directors
December 2025 2. "Proposal on Increasing Capital for Subsidiary Plasma Apheresis Stations"
9 Business Meeting Sixth
March 3 3. "Proposal on Signing the "Blood Products Technical Cooperation Contract""
meetings
- "Proposal on Convening the Fourth Extraordinary Shareholders' Meeting in 2025"
(2) The board of directors’ implementation of shareholders’ meeting resolutions
During the reporting period, the company held a total of 5 shareholders' meetings, all convened by the board of directors. The company's board of directors, in accordance with the "public
According to the requirements of the Judiciary, Securities Law and other relevant laws and regulations and the Articles of Association, we must strictly comply with the resolutions and authorizations of the shareholders' meeting and conscientiously implement the resolutions passed by the shareholders' meeting. The specific situation is as follows:
Serial number Meeting name Meeting time Proposal to be considered
"Proposal on the 2024 Annual Report and its Summary"
"Proposal on the 2024 Board of Directors Work Report"
2024 Annual Shares 2025 5
1 3. "Proposal on the Work Report of the Board of Supervisors in 2024"
East Conference March 19
"Proposal on the Profit Distribution Plan for 2024"
"Proposal on Increasing Comprehensive Credit Lines of Banks"
"Proposal on Amending the Articles of Association and Handling Industrial and Commercial Change Registration" 2. "Proposal on Amending the Company's Related Systems"
No. 1 in 2025
2025 July 3. "About the general election and nomination of the company's board of directors for the fourth session of the board of directors, not the only temporary shareholder
March 17th Proposal for Establishing Director Candidates"
General Assembly
"Proposal on the General Election of the Company's Board of Directors and Nomination of Independent Director Candidates for the Fourth Board of Directors"
"Proposal on Complying with the Conditions for Issuing A Shares to Specific Objects" 2. "Proposal on the Plan for Issuing A Shares to Specific Objects in 2025"
"Proposal on the Plan for Issuing A Shares to Specific Targets in 2025"
"Proposal on the Demonstration and Analysis Report on the Plan of Issuing A Shares to Specific Targets in 2025"
"About the issuance of A-shares to specific objects to raise funds in 2025. The second issue in 2025
Proposal to use feasibility analysis report in 2025-8
3 temporary shareholders
June 7th 6. "Proposal on No need to prepare a report on the use of funds raised in the previous round" meeting
"Proposal on the issuance of A shares to specific objects in 2025 to dilute current shareholder returns, filling measures and commitments of relevant entities"
"Proposal on requesting the shareholders' meeting to authorize the board of directors or persons authorized by the board of directors to fully handle matters related to the issuance of A shares to specific objects" 9. "Proposal on the shareholder dividend return plan for the next three years (2025-2027)"
"Proposal on the Remuneration Plan for the Directors of the Fourth Board of Directors of the Company" 11. "Proposal on the Investment in the Weiguang Bio-Intelligent Industrial Base Project" The third date of 2025
11, 2025
4th temporary shareholder "Proposal on Renewal of the Audit Institution for 2025"
March 27
Will
4th in 2025
December 2025
5th temporary shareholder "Proposal on Applying for a Comprehensive Credit Line from the Bank"
March 22
Will
(3) Performance of duties by special committees
During the reporting period, the company’s board of directors set up various special committees in accordance with the Articles of Association and the corresponding special committees.
The committee carries out its work in accordance with the rules of procedure, gives full play to its professional advantages, conducts research and reviews on matters involving corporate governance, board of directors election, development strategy, remuneration assessment and other matters, and puts forward opinions and suggestions to the board of directors, providing important support for the board of directors' scientific decision-making.
- Audit Committee
The company's audit committee held 6 meetings to review and supervise the company's financial reports, internal control evaluation reports, issuance of stocks to specific objects, renewal of accounting firms and other matters, and effectively guided and supervised the company's financial, risk control and internal control management related work.
2.Nomination Committee
The company's nomination committee held three meetings to conduct a comprehensive review and verification of the qualifications, professional background, independence, etc. of the candidates for the company's fourth board of directors, and confirmed that the candidates' qualifications met the requirements of laws and regulations. Verify the qualifications, performance conditions, and professional competencies of the senior managers to be appointed by the company to confirm that there are no circumstances prohibiting the relevant personnel from serving as senior managers of the company and that the relevant nomination procedures are legal and compliant.
- Remuneration and Appraisal Committee
The company's remuneration and assessment committee held two meetings to review the draft revision of the company's third employee stock ownership plan and the fourth remuneration plan for directors and senior managers. The relevant procedures complied with laws, regulations and company system requirements.
4.Strategy Committee
The company's strategy committee held a meeting to review proposals such as the company's issuance of shares to specific objects and the construction of an intelligent industrial base project. Based on industry development and trends and the company's actual operating conditions, it put forward rational suggestions and actively performed the responsibilities of the strategy committee.
(4) Corporate governance
During the reporting period, the company successfully completed the election of the board of directors and the appointment of senior managers to ensure the standardization and continuity of the board of directors' operations. At the same time, the company carefully sorted out its internal management system in accordance with the requirements of the latest "Company Law", "Code of Corporate Governance for Listed Companies" and other laws, regulations and normative documents, and combined with the actual situation of the company, revised and improved 14 important internal management systems including the "Articles of Association", "Rules of Procedure for Shareholders' Meetings", "Rules of Procedure for Board of Directors", etc., further solidifying the foundation of the company's standardized governance, building a more complete internal control and compliance management system, and continuously improving the level of corporate governance.
(5) Capital operation situation
In 2025, the company launched a project to issue A shares to specific targets. The total amount of funds planned to be raised shall not exceed 1.5 billion yuan (including the principal amount). After deducting the issuance expenses, the raised funds will be used for the company's intelligent industry base project and supplementary working capital. During the reporting period, the board of directors actively promoted the company's work on issuance of shares to specific objects, completed issuance plan demonstration, internal decision-making review and other relevant procedures as required, and fulfilled its information disclosure obligations in a timely manner. During the review process, we actively communicated and collaborated with relevant departments and intermediary agencies, completed inquiries and responses in a timely manner and disclosed them to the public, strictly followed regulatory requirements, and standardized and promoted all work. As of the date of this report, this project has been submitted to the China Securities Regulatory Commission for registration procedures.
(6) Duty performance of independent directors
During the reporting period, the company’s independent directors strictly followed laws and regulations such as the Company Law, the Securities Law, the Measures for the Administration of Independent Directors of Listed Companies, as well as the Articles of Association and the Working System of Independent Directors. They performed their duties conscientiously and diligently, carefully reviewed the board meeting materials, attended relevant meetings in person, and exercised their voting rights prudently. At the same time, independent directors understand the company's production and operation, internal control and financial operations through various channels such as communicating with the management and conducting on-site surveys, so as to effectively protect the legitimate rights and interests of the company and all shareholders, especially small and medium-sized shareholders. For details on the performance of duties by the company's independent directors, please refer to the "2025 Independent Directors' Duty Report".
(7) Issue special opinions on the self-examination of independence of independent directors
The current independent directors of the company, Ms. Wang Yanmei, Ms. Huang Juan, and Mr. Zhang Jianping, and the independent directors who have resigned during the reporting period, Mr. Wang Xinmin and Mr. Yang Xinfa, respectively submitted the "Self-examination Report on the Independence of Independent Directors" to the board of directors. Based on the self-examination report and investigation and verification, the board of directors evaluated the independence of the current independent directors and believed that none of the company's current independent directors held any position other than independent directors in the company, nor did they hold any position in the company's major shareholders. They had no interest relationship with the company and major shareholders or other relationships that might affect independent and objective judgment, and there were no other circumstances that would damage the independence of independent directors. They were in compliance with regulations such as the "Measures for the Management of Independent Directors of Listed Companies" and the provisions on the qualifications and independence of independent directors in the "Articles of Association".
3. Key tasks of the Board of Directors in 2026
(1) Strengthen strategic guidance and promote a good start in the “15th Five-Year Plan”
2026 is the first year of the "15th Five-Year Plan". The company's board of directors will adhere to the core positioning of being responsible to all shareholders, anchor the strategic goal of "China's pioneer of differentiated blood products, global platform biomedicine cutting-edge", coordinate the overall situation, make scientific decisions, and continue to promote the practical implementation of strategic initiatives. Adhere to the business philosophy of "survive by quality, develop by brand, and win the market by service", constantly consolidate the main responsibilities and main businesses, actively respond to new challenges in the industry and take the initiative to change; promote the layout of the frontier areas of biomedicine, capture new development opportunities, and enhance differentiated competitive advantages; vigorously promote the company's stock issuance project to specific objects, help the company improve new quality productivity, and lay the foundation for the company's sustainable and healthy development.
(2) Strengthen the construction of the board of directors and improve the efficiency of corporate governance
In 2026, the company will continue to build a professional, efficient and standardized board of directors and continuously improve the level of corporate governance. The board of directors will give full play to its core role in corporate governance, do a solid job in daily work, and make decisions on major matters scientifically and efficiently. Regularly review the company's internal management system, combine regulatory requirements and the actual situation of corporate governance, timely revise the "Articles of Association" and supporting systems to ensure the standardization and effectiveness of the board of directors' operations; continue to strengthen the support for directors' performance of duties, and listen to the important suggestions of independent directors and special committees in strategic guidance, risk prevention and control, audit supervision, etc., to provide a solid guarantee for the company's scientific decision-making; practice the concept of sustainable development, give full play to the important role of ESG management in risk control, operation optimization and strategic policy implementation, and escort the company's high-quality development with high-quality governance.
(3) Standardize information disclosure and deepen investor relations management
The board of directors will supervise the company's daily information disclosure work in accordance with the provisions of the Company Law, Securities Law, Information Disclosure Management Measures for Listed Companies, Stock Listing Rules of the Shenzhen Stock Exchange, etc., continue to strictly control the quality of information disclosure, and ensure that information disclosure is true, accurate, complete, timely and fair. At the same time, we continue to improve diversified investor communication channels, and respond to investor concerns in a timely manner through hotlines, emails, Shenzhen Stock Exchange interactive transactions, on-site surveys, shareholders' meetings, performance briefings, etc., fully convey the company's value, and continue to enhance the company's capital market image and investor recognition.
Board of Directors of Shenzhen Weiguang Biological Products Co., Ltd.
April 23, 2026